Drug intelligence / Profile preview

TriGem

Development stage: Preclinical
Modality: Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral, Intranasal, Intramuscular

Overview

TriGem is an anti-idiotype antibody designed to mimic the disialoganglioside GD2. It is being investigated as a vaccine in clinical trials for patients with advanced melanoma, aiming to induce an immune response against GD2-expressing tumor cells.

Other names: ganglidiomabmAb1A7mAb-1A7mAb 1A7TriGem

Targets

Anti-GD2 antibody idiotype

Beyond the preview

Go deeper on TriGem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriGem.

Explore the full profile